Company: NCEL
Filing Date: 2025-06-23
Form Type: F-4/A
Source: 0001213900-25-056787
Chunk: 796

Company: NewcelX Ltd.
Filing Date: 2025-06-23
Form: F-4/A
Chunk 796
---
2021, the Company’s Board of Directors, following the audit committee’s approval, approved the Company’s entry into an investment agreement with each of Prof. Revel and Mr. Ruggieri, who are interested parties in the Company (hereinafter, the “Investment Agreements” and the “Interested Parties”). In the Investment Agreements, it was determined that in exchange for a total of USD $2.1 million (Prof. Revel — USD $1.1 million; Mr. Ruggieri — USD $1 million), the Company would issue to them, in accordance with their investment ratio, 1,550,478 Shares, so that Prof. Revel would be issued 804,383 Shares, and Mr. Ruggieri would be issued 746,095 Shares, and that in exchange for USD $1.5 million, the Company will repay loans that had been received from an interested party before, whose repayment date has passed. Prof. Revel would be repaid USD $1.1 million by the Company, Mr. Ruggieri would be repaid USD $0.4 million, and the remaining amount, USD $0.6 million, was received in cash from Mr. Ruggieri. On December 7, 2021, the general meeting of shareholders authorized the Investment Agreements. On December 23, 2021, the full consideration was received and the transaction was completed. H.On November 23, 2021, the Board of Directors approved a private placement agreement (the “Placement”) in the amount of USD $3.2 million (the “Investment Amount”) with Ilex Medical Ltd (hereinafter, the “Investor”). The agreement with the Investor was signed on November 24, 2021. As part of the Placement, the Investor would be issued 2,345,216 ordinary shares. In addition, the Investor would be issued 1,407,130 non -marketablewarrants eligible for conversion into 1,407,130 marketable shares without consideration. The offered warrants would be issued in two series. The warrants’ exercise prices would be USD $2.3 and USD $2.7. The warrants would be exercisable from the date of their issuance until December 31, 2023 and December 31, 2024, respectively. The full consideration was received on December 28, 2021, and the Company issued shares and warrants in accordance with the Placement Agreement. As of December 31, warrants